ECOG-ACRIN Biorepositories to Support NCTN

 描述（由申请人提供）：ECOG-ACRIN（EA）代表ECOG和ACRIN的合并，形成一个合作小组，专注于从癌症预防和早期检测到晚期疾病管理及其影响的癌症护理连续体中改变实践的临床和转化研究。此应用程序用于支持NCI国家临床试验网络（NCTN）五个生物样本库之一的基础设施和银行业务。NCTN银行将共同形成一个综合网络，并将相互合作，并与附属的NCTN集团统计和数据管理中心，运营办公室，其他NCTN单位，NCI赞助的项目和调查人员以及NCI合作。其目标是确保从参与NCI资助的NCTN III期和大型II期临床治疗试验的癌症患者中采集、储存和分发注释良好的人类生物标本。EA的具体目标是：1）收集、处理、储存、分类和分发恶性和非恶性组织、细胞、血液和其他液体标本及其衍生物（DNA，RNA和蛋白质），并将样本与NCTN计划内的相关临床，病理和分子数据联系起来; 2）开发和利用常规和创新的生物标本资源，这将有助于成功完成基于完整生物标志物的NCTN支持的临床试验和相关的相关研究，以促进新的生物标志物驱动的个性化癌症治疗策略的开发; 3）发展对来自EA临床试验患者的组织、细胞、血液和其他基于体液的标本进行经典和分子方法学的能力，包括计划中的未来基于生物素的功能的巩固，并与领导相关NCTN支持的临床试验的研究人员密切合作，提供对研究结果的专家解释;以及4）协助NCTN内外的研究人员通过IT Navigator和NCTN生物样本“前门”服务访问生物样本进行研究，并积极参与，领导，并协调NCI格鲁库委员会（GBC）、NCI实验治疗药物临床试验网络（ETCTN）和其他国立卫生研究院（NIH）/NCI支持的样本库组织的活动。

 DESCRIPTION (provided by applicant): ECOG-ACRIN (EA) represents the merger of ECOG and ACRIN to form a cooperative group focused on practice-changing clinical and translational research across the cancer care continuum from cancer prevention and early detection, through the management of advanced disease and its impact. This application is to support the infrastructure and banking operations for one of the five NCI National Clinical Trials Network (NCTN) Biospecimen Banks. Together, the NCTN Banks will form an integrated network and will collaborate with each other and with affiliated NCTN Group Statistics and Data Management Centers, Operations Offices, other NCTN units, NCI-sponsored programs and investigators, and the NCI. The goal is to ensure the collection, storage, and distribution of well-annotated human biospecimens, procured from cancer patients participating in NCI-funded NCTN Phase III and large Phase II clinical treatment trials. EA's Specific Aims are: 1) To collect, process, store, catalog, and distribute malignant and non-malignant tissues, cells, blood, and other fluid specimens and their derivatives (DNA, RNA, and protein) from patients enrolled in EA clinical trials following the NCI's "Best Practices for Biospecimen Resources" and to link the specimens to relevant clinical, pathologic, and molecular data within the NCTN program; 2) To develop and utilize both routine and innovative biospecimen resources that will aid in the successful completion of NCTN-supported clinical trials based on integral biomarkers and of related correlative studies to promote the development of novel biomarker-driven personalized cancer therapeutic strategies; 3) To develop capabilities for performing classic and molecular methodologies on tissue, cell, blood, and other body fluid-based specimens from EA clinical trial patients, including planned future consolidation of specimen-based functions, and provide expert interpretation of the findings in close collaboration with the investigators leading the related NCTN-supported clinical trials; and 4) To assist investigators outside and within the NCTN to access biospecimens for research via IT Navigator and NCTN Biospecimen "front door" services, and to participate actively in, lead, and coordinate the activities of the NCI Grou Banking Committee (GBC), the NCI Experimental Therapeutics Clinical Trials Network (ETCTN), and other National Institutes of Health (NIH)/NCI-supported specimen banking organizations.